Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 70
- Registration Number
- NCT00328770
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Comparison of Sirolimus and Azathioprine in Lung Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 181
- Registration Number
- NCT00321906
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- Office of Rare Diseases (ORD)
- Target Recruit Count
- 52
- Registration Number
- NCT00319878
- Locations
- 🇺🇸
Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸UCLA Center for Health Sciences, Los Angeles, California, United States
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 18
- Registration Number
- NCT00317798
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
- Conditions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2010-05-07
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00317785
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00311311
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2010-06-30
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 100
- Registration Number
- NCT00306397
- Locations
- 🇨🇭
University Hospital Basel, Clinic for Transplantation Immunology and Nephrology, Basel, Switzerland
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 295
- Registration Number
- NCT00305682
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2006-03-21
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 80
- Registration Number
- NCT00305396
- Locations
- 🇺🇸
Vanderbilt University Medical Center/Nashville VA, Nashville, Tennessee, United States
Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2007-05-15
- Target Recruit Count
- 94
- Registration Number
- NCT00290069
- Locations
- 🇪🇸
Hospital Universitario Marqués de Valdecilla, Santander, Spain
🇪🇸Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.